(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Infectious Diseases Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets's offering.

Fully revised and updated, the report provides details of 1,786 infectious diseases deals from 2019 to 2025.
Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious diseases deals entered into by the world's leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report's initial chapters offer an orientation to infectious diseases dealmaking and business activities. Chapter 1 introduces the report, while Chapter 2 analyzes trends in infectious diseases dealmaking. Chapter 3 details the financial terms of deals, sectioned by headline value, upfront payment, milestone payment, and royalty rates. Chapter 4 reviews the top 25 most active biopharma companies in the field. Chapter 5 provides a detailed review of infectious diseases deals since 2019, with online access to contract documents. Chapter 6 includes a directory of deals categorized by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in infectious diseases deal making since 2019. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Infectious Diseases Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse infectious diseases collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in infectious diseases dealmaking
2.1. Introduction
2.2. Infectious diseases partnering over the years
2.3. Infectious diseases partnering by deal type
2.4. Infectious diseases partnering by industry sector
2.5. Infectious diseases partnering by stage of development
2.6. Infectious diseases partnering by technology type
2.7. Infectious diseases partnering by therapeutic indication
Chapter 3 - Financial deal terms for infectious diseases partnering
3.1. Introduction
3.2. Disclosed financials terms for infectious diseases partnering
3.3. Infectious diseases partnering headline values
3.4. Infectious diseases deal upfront payments
3.5. Infectious diseases deal milestone payments
3.6. Infectious diseases royalty rates
Chapter 4 - Leading infectious diseases deals and dealmakers
4.1. Introduction
4.2. Most active in infectious diseases partnering
4.3. List of most active dealmakers in infectious diseases
4.4. Top infectious diseases deals by value
Chapter 5 - Infectious diseases contract document directory
5.1. Introduction
5.2. Infectious diseases partnering deals where contract document available
Chapter 6 - Infectious diseases dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by infectious diseases therapeutic target
Deal directory
Deal directory - Infectious diseases deals by company A-Z 2019 to 2025
Deal directory - Infectious diseases deals by technology type 2019 to 2025
Deal type definitions

Companies Featured

• Aardvark Therapeutics
• AbbVie
• Acelrx Pharmaceuticals
• AiCuris
• Alnylam Pharmaceuticals
• Altamira Therapeutics
• Amgen
• Aphex BioCleanse Systems
• Applied DNA Sciences
• Arbutus
• Artisan Bio
• AstraZeneca
• Atara Biotherapeutics
• Bayer
• Biogen
• Boehringer Ingelheim
• Boston University
• Bristol-Myers Squibb
• CSL Behring
• Ginkgo BioWorks
• GlaxoSmithKline
• Janssen Pharmaceuticals
• Johns Hopkins University
• Johnson & Johnson
• Merck & Co.
• Moderna
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Roche
• Sandoz
• Sartorius AG
• Serman Pharmaceuticals
• Sanofi
• St. Jude Children's Research Hospital
• Takeda Pharmaceuticals
• Themis Bioscience
• Thermo Fisher Scientific
• University of California, San Diego
• University of Oxford
• University of Washington
• Vaccine Research Center (NIH)
• VBI Vaccines
• Verily Life Sciences
• Vir Biotechnology
• Viva Biotech
• WuXi Biologics
• Yale University
• Zoetis
• Zymeworks

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112025004107003653ID1110368230